Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Hanshen Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5220-1996; OpenAlex author ID A5020463692. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers

Papers 10

  1. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Co-author DOI 10.1002/cac2.70038↗
  2. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63146-2↗
  3. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  4. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2024.101731↗
  5. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  6. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
  7. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Co-author DOI 10.1038/s41388-023-02711-9↗
  8. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗
  9. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. Co-author DOI 10.3390/cancers15082225↗
  10. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Co-author DOI 10.1038/s41388-021-01763-z↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 10 shared papers, 2021–2025 · strength 1.70
  2. Lihong He · 9 shared papers, 2023–2025 · strength 1.58
  3. Tingbo Liang · 9 shared papers, 2021–2025 · strength 1.48
  4. Kang Sun · 8 shared papers, 2023–2025 · strength 1.37
  5. Xiaozhen Zhang · 8 shared papers, 2021–2025 · strength 1.36
  6. Mengyi Lao · 8 shared papers, 2021–2025 · strength 1.36
  7. Jian Xu · 4 shared papers, 2021–2024 · strength 0.61
  8. Yi Duan · 3 shared papers, 2021–2023 · strength 0.44
  9. Lingyue Liu · 2 shared papers, 2025 · strength 0.36
  10. Xiongbin Lu · 2 shared papers, 2025 · strength 0.36
  11. Yan Chen · 2 shared papers, 2023–2025 · strength 0.34
  12. Daqian Xu · 1 shared paper, 2025 · strength 0.22
  13. Tingbo Liang · 1 shared paper, 2025 · strength 0.22
  14. Junming Huang · 1 shared paper, 2025 · strength 0.19
  15. Xinyuan Liu · 1 shared paper, 2025 · strength 0.19
  16. Qingbo Meng · 1 shared paper, 2024 · strength 0.17
  17. Xiao Zhi · 1 shared paper, 2025 · strength 0.17
  18. Xiang Li · 1 shared paper, 2025 · strength 0.17
  19. Mao Ye · 1 shared paper, 2025 · strength 0.17
  20. Jinyuan Song · 1 shared paper, 2025 · strength 0.17
  21. Zhengtao Hong · 1 shared paper, 2023 · strength 0.14
  22. Yifan Hong · 1 shared paper, 2023 · strength 0.14
  23. Tao Ma · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.